Confronting the challenges of discovery of novel antibacterial agents

被引：65
作者：
Singh, Sheo B. [1 ]
机构：
[1] SBS Pharma Consulting LLC, Edison, NJ 08820 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2014年 / 24卷 / 16期
关键词：
Antibacterial; Antimicrobial; Topoisomerase II; Phenotypic screening; Discovery strategy; BACTERIAL TOPOISOMERASE INHIBITORS; DNA GYRASE INHIBITORS; IN-VITRO ACTIVITY; POTENT INHIBITORS; II TOPOISOMERASES; NATURAL-PRODUCTS; DESIGN; ISOTHIAZOLOQUINOLONES; 7-POSITION; SPECTRUM;
D O I：
10.1016/j.bmcl.2014.06.053
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Bacterial resistance is inevitable and is a growing concern. It can be addressed only by discovery and development of new agents. However the discovery and development of new antibacterial agents are at an all time low. This article broadly examines the historical as well as current status of antibacterial discovery and provides some perspective as how to address some of the challenges. (C) 2014 The Author. Published by Elsevier Ltd.
引用
收藏
页码：3683 / 3689
页数：7
相关论文
共 73 条
[1]  
Alm R. A., 2013, 53 INT C ANT AG CHEM
[2]  
Basarab G. S., 2013, 53 INT C ANT AG CHEM
[3]   Type IIA topoisomerase inhibition by a new class of antibacterial agents [J].
Bax, Benjamin D. ;
Chan, Pan F. ;
Eggleston, Drake S. ;
Fosberry, Andrew ;
Gentry, Daniel R. ;
Gorrec, Fabrice ;
Giordano, Ilaria ;
Hann, Michael M. ;
Hennessy, Alan ;
Hibbs, Martin ;
Huang, Jianzhong ;
Jones, Emma ;
Jones, Jo ;
Brown, Kristin Koretke ;
Lewis, Ceri J. ;
May, Earl W. ;
Saunders, Martin R. ;
Singh, Onkar ;
Spitzfaden, Claus E. ;
Shen, Carol ;
Shillings, Anthony ;
Theobald, Andrew J. ;
Wohlkonig, Alexandre ;
Pearson, Neil D. ;
Gwynn, Michael N. .
NATURE, 2010, 466 (7309) :935-U51
[4]   Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases [J].
Black, Michael T. ;
Stachyra, Therese ;
Platel, Denis ;
Girard, Anne-Marie ;
Claudon, Monique ;
Bruneau, Jean-Michel ;
Miossec, Christine .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (09) :3339-3349
[5]  
Black MT, 2009, CURR OPIN INVEST DR, V10, P804
[6]  
Bouchillon S. K., 2013, 53 INT C ANT AG CHEM
[7]   New natural products as new leads for antibacterial drug discovery [J].
Brown, Dean G. ;
Lister, Troy ;
May-Dracka, Tricia L. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (02) :413-418
[8]   Structure-Based Discovery of Substituted 4,5′-Bithiazoles as Novel DNA Gyrase Inhibitors [J].
Brvar, Matjaz ;
Perdih, Andrej ;
Renko, Miha ;
Anderluh, Gregor ;
Turk, Dusan ;
Solmajer, Tom .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (14) :6413-6426
[9]   Phenotypic Screening as a Strategic Component of Drug Discovery Programs Targeting Novel Antiparasitic and Antimycobacterial Agents: An Editorial Miniperspectives Series on Phenotypic Screening for Antiinfective Targets [J].
Butera, John A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (20) :7715-7718
[10]   A convergent enantioselective route to structurally diverse 6-deoxytetracycline antibiotics [J].
Charest, MG ;
Lerner, CD ;
Brubaker, JD ;
Siege, DR ;
Myers, AG .
SCIENCE, 2005, 308 (5720) :395-398
12345678